Effect of 3-day dasatinib treatment on levels of regulatory T cells and vaccine-mediated antigen-specific CD8⁺ T-cell responses. (A) Representative dot plots for Treg staining in the peripheral blood of tumor-bearing mice. (B) Percentages of Treg cells in CD4⁺ T cells in the peripheral blood of tumor-bearing mice on day 11 (***P < .0001). (C) Treg/ T effector ratio in the peripheral blood of tumor-bearing mice on day 11 (***P < .0001). (D) Percentages of Treg cells in CD4⁺ T cells in tumors on day 11 (*P = .0473). (E) Effect of dasatinib on proportions of Treg cells and Treg/T effector ratios in tumor-free mice (**P = .0026, *P = .0432). (F) Representative dot plots for P1A tetramer staining in the peripheral blood on day 7 after vaccination. (G) Effect of 3-day dasatinib treatment on vaccine-mediated P1A-specific CD8⁺ T-cell responses (***P < .0001).